Previously founder and CEO of Celsion Corporation in the US and professor at the University of Maryland, Dr. Cheung is a well known microwave expert and has presented papers internationally. He has raised significant capital in the past for Celsion and successfully developed multiple focused heat based tumor targeting cancer treatment devices and pharmaceuticals. Dr. Cheung received a PhD in Electrical Engineering, from the University of Maryland.
Significant life sciences experience, Mr. Mon is previously V.P. of business and product development, General Manager, and Director of Celsion. He achieved FDA approvals for IDE/PMA/510K submissions, and has worked with clinicians, engineers, and patent attorneys on thermotherapy and breast-cancer-related devices. Mr. Mon has co-authored several scholarly articles and holds many granted and pending patents in the area of thermotherapy for the treatment of cancer and other diseases.
Mirsad Jakubovic is a Chartered Accountant. Mr. Jakubovic’s experience includes work as the Director of Finance and Administration for Havana House Cigar and Tobacco Merchants Ltd. and as Director of Finance and Administration for Swatch Group Canada Ltd. Mr. Jakubovic received his EMBA from the Richard Ivey School of Business and his B.Comm. from the University of Toronto.
Mr. O’Neill was the Controller and Chief Financial Officer at Celsion Corporation where he later became the Director of Prolieve Clinical Trials and Director of Prolieve Product Development with primary responsibility for managing pivotal clinical studies required to gain official approval from the FDA for Prolieve. Following FDA’s approval for the commercialization of Prolieve, Mr. O’Neill was named as designated principal intermediary between the company and its marketing partner, Boston Scientific Corporation. Subsequently, he was Boston Scientific’s Business Development Manager—Prolieve® System, Atlantic Region before joining Medifocus Inc. as its Vice President of Sales and Finance in charge of Prolieve sales.